Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB)
Since my October article , Biogen Inc. ( BIIB ) stock has risen 18.4%, outperforming the S&P 500 [2.9% return] ( SPY ), as well as two "bellwethers" for the biotech investors, the iShares Biotechnology ETF [14%] (With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...